{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:11:52Z","timestamp":1794381112858,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>FOLFOX is widely used in the treatment of colon cancer. The combination of oxaliplatin (OXA), 5-fluorouracil (5-FU), and leucovorin (LV) is administrated according to strict protocols. Based on incompatibility studies, LV and OXA are supplied concurrently via intravenous infusion, followed by intravenous administration of 5-FU. This study aims at determining the stability of the binary mixture of OXA and LV diluted in infusion bags containing either 5% dextrose or normal saline compared with their single solutions besides single solutions of 5-FU at two temperatures (room temperature and refrigeration) for two weeks. HPLC diode array detection method was developed and validated to simultaneously determine the three drugs. Stability studies in 5% dextrose solution revealed that mixtures of OXA and LV kept at room temperature showed chemical degradation for OXA, with better stability for refrigerated solutions. Generally, single solutions showed considerable stability. Using normal saline, a combination of OXA\/LV showed relative stability of LV over the 15 days of study with marked degradation of OXA. 5-FU was relatively stable in 5% dextrose and normal saline at both temperatures. Method\u2019s applicability was extended to the determination of the cited drugs in plasma and colonic media samples. Method\u2019s sustainability, blueness, and whiteness were investigated.<\/jats:p>","DOI":"10.1038\/s41598-025-02079-8","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:58:39Z","timestamp":1748008719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sustainability-based comparative stability of oxaliplatin plus leucovorin and 5-fluorouracil in infusion bags with application to plasma and colonic media samples"],"prefix":"10.1038","volume":"15","author":[{"given":"Hadir M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma Mahmoud","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekram M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira Fawzy","family":"El-Yazbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2079_CR1","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3390\/cancers12092679","volume":"12","author":"J Taieb","year":"2020","unstructured":"Taieb, J. & Gallois, C. Adjuvant chemotherapy for stage III colon cancer. Cancers 12, 2679 (2020).","journal-title":"Cancers"},{"key":"2079_CR2","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cancers14071732","volume":"14","author":"MS Hossain","year":"2022","unstructured":"Hossain, M. S. et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14, 1732 (2022).","journal-title":"Cancers"},{"key":"2079_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247\u2013257 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2079_CR4","first-page":"07","volume":"3","author":"BI Bagus","year":"2019","unstructured":"Bagus, B. I. Gastrointestinal related symptoms on FOLFIRI regiments in resectable stage III colorectal cancer patients: A retrospective study. Int. J. Surg. 3, 07\u201308 (2019).","journal-title":"Int. J. Surg."},{"key":"2079_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14740338.2010.511610","volume":"9","author":"SE Mikhail","year":"2010","unstructured":"Mikhail, S. E., Sun, J. F. & Marshall, J. L. Safety of capecitabine: a review. Exp. Opin. Drug Saf. 9, 831\u2013841 (2010).","journal-title":"Exp. Opin. Drug Saf."},{"key":"2079_CR6","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves, C. et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352, 2696\u20132704 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2079_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1245\/ASO.2006.07.003","volume":"13","author":"T Andre","year":"2006","unstructured":"Andre, T. et al. Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol. 13, 887\u2013898 (2006).","journal-title":"Ann. Surg. Oncol."},{"key":"2079_CR8","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109\u20133116 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2079_CR9","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1200\/JCO.22.02773","volume":"41","author":"A de Gramont","year":"2023","unstructured":"de Gramont, A. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 41, 5080\u20135089 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2079_CR10","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.ejon.2004.06.009","volume":"8","author":"S Faithfull","year":"2004","unstructured":"Faithfull, S. & Deery, P. Implementation of capecitabine (Xeloda\u00ae) into a cancer centre: UK experience. Eur. J. Oncol. Nurs. 8, S54\u2013S62 (2004).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"2079_CR11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/cancers2031717","volume":"2","author":"K Miura","year":"2010","unstructured":"Miura, K. et al. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers 2, 1717\u20131730 (2010).","journal-title":"Cancers"},{"key":"2079_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/BF02440861","volume":"44","author":"J Zittoun","year":"1993","unstructured":"Zittoun, J. et al. Pharmacokinetic comparison of leucovorin and levoleucovorin. Eur. J. Clin. Pharmacol. 44, 569\u2013573 (1993).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2079_CR13","doi-asserted-by":"publisher","first-page":"111657","DOI":"10.1016\/j.jinorgbio.2021.111657","volume":"226","author":"T Marzo","year":"2022","unstructured":"Marzo, T. et al. Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells. J. Inorg. Biochem. 226, 111657.  (2022).","journal-title":"J. Inorg. Biochem."},{"key":"2079_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/2212697X05666180905094942","volume":"5","author":"G Sharma","year":"2018","unstructured":"Sharma, G., Anghore, D., Khare, R. & Rawal, R. K. Oxaliplatin for colorectal cancer therapy: A review. Clin. Cancer Drugs. 5, 13\u201327 (2018).","journal-title":"Clin. Cancer Drugs"},{"key":"2079_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno, P. M. et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23, 461\u2013471.  (2017).","journal-title":"Nat. Med."},{"key":"2079_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.bjc.6600185","volume":"86","author":"J Fischel","year":"2002","unstructured":"Fischel, J. et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br. J. Cancer. 86, 1162\u20131168 (2002).","journal-title":"Br. J. Cancer"},{"key":"2079_CR17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/10781552211020808","volume":"28","author":"C Al Sabbagh","year":"2022","unstructured":"Al Sabbagh, C., Agapova, E., Boudy, V. & Mignet, N. Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture. J. Oncol. Pharm. Pract. 28, 1303\u20131314.  (2022).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2079_CR18","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1002\/jps.10201","volume":"91","author":"E Jerremalm","year":"2002","unstructured":"Jerremalm, E. et al. Alkaline hydrolysis of oxaliplatin\u2014isolation and identification of the oxalato monodentate intermediate. J. Pharm. Sci. 91, 2116\u20132121 (2002).","journal-title":"J. Pharm. Sci."},{"key":"2079_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0162-0134(00)00208-7","volume":"84","author":"S Verstraete","year":"2001","unstructured":"Verstraete, S., Heudi, O., Cailleux, A. & Allain, P. Comparison of the reactivity of oxaliplatin, Pt (diaminocyclohexane) Cl2 and Pt (diaminocyclohexane1)(OH2) 22\u2009+\u2009with Guanosine and L-methionine. J. Inorg. Biochem. 84, 129\u2013135 (2001).","journal-title":"J. Inorg. Biochem."},{"key":"2079_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","volume":"479","author":"AM Mehta","year":"2015","unstructured":"Mehta, A. M. et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int. J. Pharm. 479, 23\u201327.  (2015).","journal-title":"Int. J. Pharm."},{"key":"2079_CR21","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.4172\/2161-0398.1000e101","volume":"2","author":"Y Yoshida","year":"2012","unstructured":"Yoshida, Y. Oxaliplatin and pH. J. Phys. Chem. Biophys. 2, 2161 (2012).","journal-title":"J. Phys. Chem. Biophys."},{"key":"2079_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1191\/1078155202jp088oa","volume":"8","author":"LA Trissel","year":"2002","unstructured":"Trissel, L. A., Saenz, C. A., Ingram, D. S. & Ogundele, A. B. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J. Oncol. Pharm. Pract. 8, 33\u201337 (2002).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2079_CR23","first-page":"189","volume":"82","author":"G Milano","year":"1995","unstructured":"Milano, G. & Renee, N. Physicochemical compatibility of 5-fluorouracil (new French preparation) and folinic acid. Bull. Cancer. 82, 189\u2013195 (1995).","journal-title":"Bull. Cancer"},{"key":"2079_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/ajhp\/52.7.710","volume":"52","author":"FASHP Trissel","year":"1995","unstructured":"Trissel, F. A. S. H. P., Martinez, L. A., Xu, Q. A. & J. F. & Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am. J. Health-system Pharm. 52, 710\u2013715 (1995).","journal-title":"Am. J. health-system Pharm."},{"key":"2079_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0731-7085(95)01635-X","volume":"14","author":"P Martel","year":"1996","unstructured":"Martel, P. et al. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J. Pharm. Biomed. Anal. 14, 395\u2013399 (1996).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2079_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0142-9612(98)00221-X","volume":"20","author":"T Dine","year":"1999","unstructured":"Dine, T. et al. Effects of PVC bags sterilization process on the 5-fluorouracil stability. Biomaterials 20, 655\u2013661 (1999).","journal-title":"Biomaterials"},{"key":"2079_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1191\/1078155203jp109oa","volume":"9","author":"S Roberts","year":"2003","unstructured":"Roberts, S. & Sewell, G. J. Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump\u00ae. J. Oncol. Pharm. Pract. 9, 109\u2013112 (2003).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2079_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4212\/cjhp.v62i1.115","volume":"62","author":"L Galanti","year":"2009","unstructured":"Galanti, L. et al. Long-term stability of 5-Fluorouracil in 0.9% sodium chloride after freezing, microwave thawing, and refrigeration. Can. J. Hosp. Pharm. 62, 34 (2009).","journal-title":"Can. J. Hosp. Pharm."},{"key":"2079_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/ddt.2022.01011","volume":"16","author":"C Komm","year":"2022","unstructured":"Komm, C., Rochani, A., Fox, T. & Kaushal, G. Stability of extemporaneously compounded 5-fluorouracil utilizing high performance liquid chromatography. Drug Discoveries Ther. 16, 1\u20137 (2022).","journal-title":"Drug Discoveries Ther."},{"key":"2079_CR30","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.2146\/ajhp060369","volume":"64","author":"P Andre","year":"2007","unstructured":"Andre, P. et al. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am. J. Health Syst. Pharm. 64, 1950\u20131954.  (2007).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2079_CR31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2146\/ajhp090039","volume":"66","author":"C Eiden","year":"2009","unstructured":"Eiden, C. et al. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in Polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am. J. Health Syst. Pharm. 66, 1929\u20131933.  (2009).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2079_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/ejhpharm-2013-000323","volume":"21","author":"MP Trojniak","year":"2014","unstructured":"Trojniak, M. P. et al. Stability of lyophilised oxaliplatin formulation in polyolefin infusion bags containing 5% dextrose injection. Eur. J. Hosp. Pharm. 21, 45\u201348.  (2014).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"2079_CR33","first-page":"90","volume":"53","author":"D Lecompte","year":"1991","unstructured":"Lecompte, D., Bousselet, M., Gayrard, D. & Poitou, P. Stability study of reconstituted and diluted solutions of calcium folinate. PHARMAZEUTISCHE Ind. 53, 90\u201394 (1991).","journal-title":"PHARMAZEUTISCHE Ind."},{"key":"2079_CR34","first-page":"301","volume":"70","author":"A Karbownik","year":"2013","unstructured":"Karbownik, A., Sza\u0142ek, E., Urjasz, H., Kadzio\u0142ka, M. & Grze\u015bkowiak, E. Stability of calcium folinate (Teva) in concentrate after re-use and in dilute infusions in 0.9% NaCl in polyethylene bags. Acta Pol. Pharm. 70, 301\u2013307 (2013).","journal-title":"Acta Pol. Pharm."},{"key":"2079_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/1078155220918025","volume":"27","author":"S Sanogo","year":"2021","unstructured":"Sanogo, S., Silimbani, P., Gaggeri, R. & Masini, C. Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin\/polyamide infusion bags. J. Oncol. Pharm. Pract. 27, 288\u2013296.  (2021).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2079_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/1078155207080118","volume":"13","author":"J Cadrobbi","year":"2007","unstructured":"Cadrobbi, J., Hecq, J. D., Vanbeckbergen, D., Jamart, J. & Galanti, L. Long-term stability of sodium folinate in dextrose 5% polyolefin bags at 4 C. J. Oncol. Pharm. Pract. 13, 99\u2013103 (2007).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2079_CR37","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2710.2009.01043.x","volume":"34","author":"M Lebitasy","year":"2009","unstructured":"Lebitasy, M. et al. Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags. J. Clin. Pharm. Therpeutics. 34, 423\u2013428.  (2009).","journal-title":"J. Clin. Pharm. Therpeutics"},{"key":"2079_CR38","unstructured":"agency, B. C. (ed) BC Cancer agency) 8 (Activated: 17 Aug 2005 Revised: 1 Oct (2020)."},{"key":"2079_CR39","doi-asserted-by":"crossref","unstructured":"Arshad, S. Simultaneous quantification of 5-Fluorouracil and leucovorin in pharmaceutical dosage form and human spiked plasma by using RPHPLC method. J. Chromatogr. Sep. Techniques.  (2014).","DOI":"10.4172\/2157-7064.1000235"},{"key":"2079_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s13738-018-1538-1","volume":"16","author":"S Handali","year":"2018","unstructured":"Handali, S., Ramezani, Z., Moghimipour, E., Rezaei, M. & Dorkoosh, F. A. A novel method for the simultaneous determination of 5-fluorouracil and oxaliplatin in new biodegradable PHBV\/PLGA nanoparticles. J. Iran. Chem. Soc. 16, 609\u2013615.  (2018).","journal-title":"J. Iran. Chem. Soc."},{"key":"2079_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/chromsci\/47.7.558","volume":"47","author":"FK Alanazi","year":"2009","unstructured":"Alanazi, F. K., Yassin, E., El-Badry, A., Mowafy, M., Alsarra, I. A. & H. A. & Validated high-performance liquid chromatographic technique for determination of 5-fluorouracil: applications to stability studies and simulated colonic media. J. Chromatogr. Sci. 47, 558\u2013563 (2009).","journal-title":"J. Chromatogr. Sci."},{"key":"2079_CR42","unstructured":"Guideline, I. H. T. Validation of analytical procedures: text and methodology. Q2 (R1) 1, 05. (2005)."},{"key":"2079_CR43","unstructured":"Miller, J. N. & Miller, J. C. Statistics and chemometrics for analytical chemistry. 5th. England: Prentice Hall, 256. (2005)."},{"key":"2079_CR44","unstructured":"Guidance, R. Validation of chromatographic methods. Center Drug Evaluation Res. (CDER) Washington 2 (1994)."},{"key":"2079_CR45","unstructured":"Rustum, Y. M. Bioavailability of high-dose oral leucovorin. Development of Folates and Folic Acid Antagonists in Cancer Chemotherapy: Innisbrook, Tarpon Springs, Florida, January 23\u201326, 1986 5, 57\u201360. (1987)."},{"key":"2079_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.phrs.2004.01.006","volume":"50","author":"F Casale","year":"2004","unstructured":"Casale, F. et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol. Res. 50, 173\u2013179 (2004).","journal-title":"Pharmacol. Res."},{"key":"2079_CR47","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham, M. A. et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. 6, 1205\u20131218 (2000).","journal-title":"Clin. Cancer Res."},{"key":"2079_CR48","first-page":"39","volume":"18","author":"C Burz","year":"2009","unstructured":"Burz, C. et al. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J. Gastrointest. Liver Dis. 18, 39\u201343 (2009).","journal-title":"J. Gastrointest. Liver Dis."},{"key":"2079_CR49","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/bcp.14444","volume":"87","author":"J Jacob","year":"2021","unstructured":"Jacob, J. et al. Systemic exposure to 5-fluorouracil and its metabolite, 5, 6\u2010dihydrofluorouracil, and development of a limited sampling strategy for therapeutic drug management of 5\u2010fluorouracil in patients with Gastrointestinal malignancy. Br. J. Clin. Pharmacol. 87, 937\u2013945 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2079_CR50","doi-asserted-by":"crossref","unstructured":"Cetinkaya, A., Kaya, S. I. & Ozkan, S. A. An overview of the current progress in green analytical chemistry by evaluating recent studies using greenness assessment tools. TrAC Trends Anal. Chemistry, 117330. (2023).","DOI":"10.1016\/j.trac.2023.117330"},{"key":"2079_CR51","doi-asserted-by":"crossref","unstructured":"Aboras, S. I. & Maher, H. M. Green adherent degradation kinetics study of Nirmatrelvir, an oral anti-COVID-19: characterization of degradation products using LC\u2013MS with insilico toxicity profile. BMC chemistry 17, 23. (2023).","DOI":"10.1186\/s13065-023-00928-z"},{"key":"2079_CR52","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.scp.2023.101163","volume":"35","author":"HK Ashour","year":"2023","unstructured":"Ashour, H. K., Kamel, S. M., El-Yazbi, F. & Maher, H. M. A green sustainable approach for the determination of a complex quintet hepatoprotective mixture using dual wavelength HPLC coupled with diode array detection: compliance with greenness and whiteness metrics. Sustainable Chem. Pharm. 35, 101163 (2023).","journal-title":"Sustainable Chem. Pharm."},{"key":"2079_CR53","doi-asserted-by":"publisher","first-page":"26719","DOI":"10.1039\/D3RA04186G","volume":"13","author":"HS Elbordiny","year":"2023","unstructured":"Elbordiny, H. S., Alzoman, N. Z., Maher, H. M. & Aboras, S. I. Tailoring two white chromatographic platforms for simultaneous Estimation of ritonavir-boosted nirmatrelvir in their novel pills: degradation, validation, and environmental impact studies. RSC Adv. 13, 26719\u201326731 (2023).","journal-title":"RSC Adv."},{"key":"2079_CR54","doi-asserted-by":"publisher","first-page":"2200951","DOI":"10.1002\/jssc.202200951","volume":"46","author":"MA Ragab","year":"2023","unstructured":"Ragab, M. A., Maher, H. M., Tarek, S. & Mahgoub, H. An eco-friendly multi\u2010analyte high\u2010performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter pylori. J. Sep. Sci. 46, 2200951 (2023).","journal-title":"J. Sep. Sci."},{"key":"2079_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","volume":"37","author":"A Ga\u0142uszka","year":"2012","unstructured":"Ga\u0142uszka, A., Migaszewski, Z. M., Konieczka, P. & Namie\u015bnik, J. Analytical Eco-Scale for assessing the greenness of analytical procedures. TRAC Trends Anal. Chem. 37, 61\u201372 (2012).","journal-title":"TRAC Trends Anal. Chem."},{"key":"2079_CR56","doi-asserted-by":"publisher","first-page":"10928","DOI":"10.3390\/molecules200610928","volume":"20","author":"M Tobiszewski","year":"2015","unstructured":"Tobiszewski, M., Mar\u0107, M., Ga\u0142uszka, A. & Namie\u015bnik, J. Green chemistry metrics with special reference to green analytical chemistry. Molecules 20, 10928\u201310946 (2015).","journal-title":"Molecules"},{"key":"2079_CR57","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1039\/D1GC02318G","volume":"23","author":"J P\u0142otka-Wasylka","year":"2021","unstructured":"P\u0142otka-Wasylka, J. & Wojnowski, W. Complementary green analytical procedure index (ComplexGAPI) and software. Green Chem. 23, 8657\u20138665 (2021).","journal-title":"Green Chem."},{"key":"2079_CR58","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J Plotka-Wasylka","year":"2018","unstructured":"Plotka-Wasylka, J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta 181, 204\u2013209.  (2018).","journal-title":"Talanta"},{"key":"2079_CR59","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE\u2014Analytical greenness metric approach and software. Anal. Chem. 92, 10076,  (2020).","journal-title":"Anal. Chem."},{"key":"2079_CR60","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi, N., Wojnowski, W., P\u0142otka-Wasylka, J. & Samanidou, V. Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality. Green Chem. 25, 7598\u20137604 (2023).","journal-title":"Green Chem."},{"key":"2079_CR61","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.scp.2023.101412","volume":"37","author":"SA Mahmoud","year":"2024","unstructured":"Mahmoud, S. A. & Abbas, A. E. F. Greenness, whiteness, and blueness assessment with spider chart solvents evaluation of HPTLC-densitometric method for quantifying a triple combination anti-Helicobacter pylori therapy. Sustainable Chem. Pharm. 37, 101412 (2024).","journal-title":"Sustainable Chem. Pharm."},{"key":"2079_CR62","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.1021\/acs.analchem.9b01872","volume":"91","author":"PM Nowak","year":"2019","unstructured":"Nowak, P. M. & Ko\u015bcielniak, P. What color is your method? Adaptation of the RGB additive color model to analytical method evaluation. Anal. Chem. 91, 10343\u201310352 (2019).","journal-title":"Anal. Chem."},{"key":"2079_CR63","doi-asserted-by":"publisher","first-page":"116223","DOI":"10.1016\/j.trac.2021.116223","volume":"138","author":"PM Nowak","year":"2021","unstructured":"Nowak, P. M., Wietecha-Pos\u0142uszny, R. & Pawliszyn, J. White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality. TRAC Trends Anal. Chem. 138, 116223 (2021).","journal-title":"TRAC Trends Anal. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02079-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:05:11Z","timestamp":1748012711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02079-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2079"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02079-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"13 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17982"}}